[Company Logo Image] Compound validation and profiling in vitro and in vivo
Improved clinical predictability of preclinical studies
Subcutaneous and orthotopic human xenografts
Genetically modified organ specific tumour models
Receptor tyrosine kinase-driven breast cancer model

         Preclinical Concept Validation

Angiogenesis in vivo Model

       

Syngeneic tumour models
Pharmacokinetic studies
  Toxicology (GLP)
  Histology (Frozen Sections and Paraffin Embedded Sections)

                      

Home Up vivoPharm Search Employment Feedback

Up Subcutaneous Orthotopic Syngeneic Angiogenesis

 

vivoPharm offers a variety of orthotopic tumour models (where the tumour grows in the appropriate environment). vivoPharm has qualified personnel to perform accurate microinjection of tumour cells into the target organ resulting in optimised tumour size variability. Due to the fact that the orthotopic tumour grows in the appropriate environment, orthotopic tumour models can result in better clinical predictability. We recommend orthotopic tumour models for secondary an tertiary screen of preselected compounds.

Organ

Cell Line

Breast MDA MB-435, MDA MB-468, MDA MB231, T47D
Colon HCT-15, Colo 205, HT29, HCT-116
Kidney A498
Lung NIH H460, NCI H596, A549
Ovary OVCAR-3
Prostate PC-3, PC-3M, Du145, LNCaP
Pancreas MIA PaCa-2
Liver SK-HEP-1  
Bone (Tibia) 4T1  
Melanoma A375
Melanoma B16BL6
Customers cell line or a cell line of your request

 

For price quotes please contact sales@vivoPharm.com

   

Send mail to webmaster@vivopharm.com with questions or comments about this web site.
Last modified: 18-Dec-2003